Buy Rating for Bristol-Myers Squibb Driven by Cobenfy’s Strong Sales Momentum and Growth Potential
Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...
Deep Dive Into Bristol-Myers Squibb Stock: Analyst Perspectives (9 Ratings)
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...
Bristol Myers says Opdivo + Yervoy cut risk of relapse by 38% in colorectal cancer
Bristol Myers Squibb (BMY) says its cancer drugs Opdivo and Yervoy improved progression-free survival in a Phase 3 trial for ...
The American Journal of Managed Care4h
Breakthrough Drugs Set to Achieve Blockbuster Status by 2030
Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.
FiercePharma3d
Bristol Myers, Pfizer tout new standards of care in colorectal cancer subtypes
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...
BioSpace3h
BioAge Stumbles Again, Drops Lead Obesity Molecule
It’s been a rocky few months for BioAge Labs, which shuttered a Phase II trial of its lead candidate azelaprag Tuesday after ...
Drugmakers modestly raise price on drugs at start of year, WSJ reports
Drugmakers raised the prices of more than 800 prescription drugs for blood pressure, cancer, and other conditions by 4% at the beginning of the ...
BioSpace1d
BMS, Pfizer Challenge Colorectal Cancer Standard Care With ASCO GI Readouts
Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...
Drugmakers Show Restraint on Price Increases in New Trump Era
Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working In The Therapeutics Segment | Delveinsight
The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...